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Immature DCs localize in peripheral tissues, 
where they are conditioned by environmen-
tal factors and act as sentinels against invading 
pathogens (1). To fulfi  ll their role, DCs constantly 
sample the microenvironment and capture 
  antigens via receptor-dependent endocyto-
sis, micropinocytosis, and macropinocytosis (2) 
for subsequent processing and presentation to 
naive CD4+ T cells. An integral step in this 
process is the activation of DCs by pathogen-
derived structures through pattern-recognition 
receptors, such as the Toll-like receptor (TLR) 
family. Upon TLR triggering, DCs up-  regulate 
surface expression of MHC class II, CD40, 
CD80, and CD86, and release a set of infl  am-
matory cytokines that are critical for full activa-
tion of naive CD4+ T cells (3). Depending on 
the quality of the DC–T-cell interaction, and 
the constituents of the local cytokine milieu, 
CD4+ T cells diff  erentiate into distinct subsets 
called Th1 and Th2. Th1 cells are primarily 
characterized by their production of IFN-γ and 
are essential for clearance of intracellular path-
ogens such as Leishmania major, whereas Th2 
cells, which produce IL-4, -5, and -13, provide 
protection from helminth parasites and drive 
the development of allergies. Th1 cell diff  eren-
tiation is largely driven by the macrophage and 
DC-derived cytokine IL-12 (4), and, indeed, 
mice genetically defi  cient in IL-12 fail to clear 
L. major infection (5, 6). Comparatively, IL-4 is 
the prototypic inducer of Th2 responses (7, 8); 
however, instead of DCs, Th2 cells, NKT cells, 
eosinophils, and basophils are the main sources 
of IL-4.
Serum, lymph, and interstitial fl  uid are key 
components of the environment in which DCs 
are typically exposed to pathogen-derived struc-
tures. Lipoproteins are the main constituents of 
this extracellular milieu, and perturbation of lipo-
protein homeostasis by environmental or ge-
netic factors leads to dyslipidemia. For instance, 
an excessive consumption of lipid-laden foods 
and/or a genetic defi  ciency in the lipid transport 
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protein, apolipoprotein E (apoE), leads to dyslipidemia. 
  Dyslipidemia is a central component of atherosclerosis and 
metabolic syndromes/pathological conditions linked to 
chronic infl  ammation and immune dysfunction (9–11). ApoE-
defi  cient (apoE−/−) and low-density lipoprotein (LDL)  receptor–
defi  cient (LDLr−/−) mice are commonly used animal models 
for atherosclerosis and dyslipidemia because when on a 
  standard chow diet they develop spontaneous dyslipidemia, 
which is characterized by increased plasma levels of very LDL 
(VLDL), LDL, total cholesterol, and triglycerides (12, 13). 
These lipoprotein abnormalities become even more severe 
under a “western-type” diet with a higher cholesterol and fat 
content (12, 13). Studies using these models have shown that 
dyslipidemia can alter B cell and CTL responses, and impair 
host responses against yeast (14), bacterial infections (15, 16), 
and viral infections (17). In addition, dyslipidemia inhibits mi-
gration of skin DCs in apoE−/− and LDLr−/− mice (18). Thus, 
dyslipidemia can impair immune responses; however, the 
  underlying mechanisms of its action remain unresolved.
We have examined the infl  uence of dyslipidemia on DC 
function, on CD4+ Th cell polarization, and on the course of 
L. major infection. Our fi  ndings indicate that dyslipidemia 
  directly aff  ects  CD8α− myeloid DCs, impairing their 
response to TLR stimulation. CD8α− DCs isolated from 
dyslipidemic mice exhibited reduced IL-12, -6, and TNF-α 
production, and they preferentially induced Th2 cell 
  diff  erentiation in vitro. Furthermore, naive CD4+ T cells 
adoptively transferred into dyslipidemic apoE−/− mice diff  er-
entiated into Th2 cells. This Th2-inducing bias, driven by 
dyslipidemia, also increased host susceptibility to L. major 
  infection, highlighting the considerable impact lipid homeo-
stasis has on host immunity.
RESULTS
Dyslipidemia increases host susceptibility 
to L. major infection
Previous investigations have shown that dyslipidemia can 
impair antiviral and antibacterial responses (14–17); how-
ever, the mechanism has yet to be identifi  ed. In particular, 
it remains unclear whether dyslipidemia leads to an overall 
immunosuppression or whether it modulates specifi  c 
  immune pathways. Thus, we used an in vivo model of L.   major 
Figure 1.  Increased susceptibility to infection with L. major in 
dyslipidemic mice. C57BL/6 (B6) and apoE−/− mice were maintained 
under a chow or HFCD for 8 wk and infected with L. major. (A) At 12 wk 
after infection, DLN cells were restimulated with PMA/ionomycin or 
L. major lysate, and expression of IFN-γ, IL-4, and -5 by CD4+ T cells was 
determined by fl  ow cytometry. The values show the percentage of IFN-γ, 
IL-4, and -5 single-positive cells. Horizontal bars indicate mean values for 
each group. (B) Representative FACS plots of DLN cells from the indicated 
mice stimulated with either PMA/ionomycin (top) or L. major lysate 
  (bottom) are shown. Gated on CD4+ T cells. (C) At 7 wk after infection, 
serum was collected and L. major–specifi  c IgG2a and IgG1 antibodies were 
measured by ELISA. Error bars represent the mean ± the SD. (D) Footpad 
swelling in mice infected with L. major. Results are expressed as the mean 
lesion (millimeters) size ± the SD. (E) Parasite burden in infected mice at 
12 wk post-infection. *, P < 0.05 compared with indicated controls. Data 
is representative of similar repeat experiments using 6–10 mice per group. JEM VOL. 204, February 19, 2007  443
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infection, where the pathways of protective immunity are well 
established. In particular, C57BL/6 mice develop a Th1 
immune response against L. major and successfully con-
trol the infection, whereas BALB/c mice develop a Th2 re-
sponse and fail to control the infection (19). ApoE−/− and 
C57BL/6 mice were maintained for 10 wk on either a nor-
mal chow diet or a high-fat/cholesterol diet (HFCD) before 
L. major parasites (WHOM/IR/-/173) were injected into 
the hind footpad. 12 wk after infection, popliteal draining 
LN (DLN) cells were isolated and restimulated with L. major 
lysate or PMA/ionomycin in vitro. Intracellular cytokine 
staining revealed that CD4+ T cells from apoE−/− mice fed 
a HFCD exhibited an increase in the number of IL-4– and 
-5–producing cells compared with C57BL/6 controls (Fig. 
1, A and B). In support of these data, L. major–specifi  c IgG2a 
serum titers were reduced in both HFCD-fed apoE−/− and 
C57BL/6 mice compared with chow diet–fed controls (Fig. 
1 C), whereas IgG1 titers were slightly elevated in HFCD-
fed apoE−/− and C57BL/6 mice as compared with chow 
diet–fed apoE−/− and C57BL/6 animals (Fig. 1 C). These 
results indicated that the CD4 T-cell response in HFCD-
fed apoE−/− mice had skewed toward a Th2-type response. 
In support of this, HFCD-fed apoE−/− mice showed increased 
footpad swelling (Fig. 1 D) and a highly increased parasite 
burden at the site of infection (Fig. 1 E). Notably, there was 
also a modest, but signifi  cant, increase in swelling and para-
site burden in chow diet–fed apoE−/− mice compared with 
chow diet–fed C57BL/6 mice (Fig. 1, D and E). Similar re-
sults were obtained using another strain of L. major parasites, 
MHOM/IL/81/FE/BNI (unpublished data). Moreover, 
wild-type C57BL/6 mice on a long-term (40 wk) high-
fat only diet (HFD) showed increased footpad swelling and 
parasite burden compared with chow diet–fed C57BL/6 
mice after L. major (WHOM/IR/-/173) infection (unpub-
lished data). Collectively, these data suggest that dyslipid-
emia promotes Th2 responses and increased susceptibility to 
L. major infection.
ApoE−/− splenic DCs preferentially induce 
Th2 cell development
Cytokine production and interactions between T cell and 
DC costimulatory molecules are key mechanisms by which 
CD4+ T-cell diff  erentiation is driven toward either the Th1 or 
Th2 subset. We assessed whether dyslipidemia infl  uenced the 
capacity of DCs to polarize naive CD4+ T cells. Cocultures 
comprised of splenic DCs and naive CD4 TCR transgenic (Tg) 
Figure 2.  Dyslipidemia promotes Th2 cell development. (A) Splenic 
DCs were purified from chow diet– or HFCD-fed C57BL/6 (B6) and 
apoE−/− mice, followed by co-culture with naive GP61-80-specifi  c CD4+ 
T cells in the presence of 10 nM GP61-80 peptide. On day 4, the proportion of 
IL-4– and IFN-γ–producing CD4+ T cells was determined by FACS. Numbers 
indicate the percentage of cells in each quadrant. (B and C) Naive GP61-80-
specifi  c CD4+ T cells (CD45.1+) were CFSE-labeled and transferred i.v. 
into the indicated mice 1 d before i.p. immunization with 40 μg GP61-80 
peptide and 5 nmol CpG. (B) After 3 d, CFSE dilution of adoptively trans-
ferred cells was determined by FACS. The frequency of cells within each 
cycle was calculated after appropriate gating on the CFSE+ populations. 
(C) After 6 d, the production of IFN-γ and IL-4 by adoptively transferred 
cells was determined by FACS. Horizontal bars indicate mean values for 
each group (n = 5–6). Error bars represent the mean ± the SD.444  DYSLIPIDEMIA NEGATIVELY REGULATES DC ACTIVATION AND TH1 RESPONSES | Shamshiev et al.
T cells specifi   c for a lymphocytic choriomeningitis virus 
  glycoprotein-derived Th cell epitope, GP61-80 (20), revealed 
that DCs isolated from HFCD-fed C57BL/6, and that 
apoE−/− mice preferentially induced IL-4–producing Th2 
cells and reduced the frequency of IFN-γ–producing Th1 
cells, as compared with DCs isolated from chow diet–fed 
C57BL/6 controls (Fig. 2 A). Next, we adoptively transferred 
CFSE-labeled naive CD4+ T cells from congeneic CD45.1+ 
Figure 3.  Dyslipidemia inhibits TLR-mediated activation and 
  infl  ammatory cytokine production of DC. Splenic DCs were isolated 
from either chow diet– or HFCD-fed C57BL/6 (B6) and apoE−/− mice. 
(A) CD40 surface expression on CD11c+ DCs after stimulation with 100 nM 
CpG. (B) Isolated cells were stimulated with the indicated doses of CpG 
for 6 h, followed by surface staining for CD11c and intracellular staining 
for IL-12p40. (C) Splenic DCs were isolated from chow diet–fed C57BL/6 
or apoE−/− mice at 30 wk of age and stimulated with 100 nM CpG, 
1 μg/ml LPS, 3 μg/ml R837, 5 μg/ml poly(I:C), 30 μg/ml zymosan, 5 μg/ml 
anti-CD40 antibodies, or a combination of anti-CD40 and CpG (100 nM) 
for 6 h, followed by surface staining for CD11c and intracellular staining 
for IL-12p40 and TNF-α. Horizontal bars indicate mean values for each 
group. (D) Splenic DCs were isolated from C57BL/6 mice fed either chow 
or HFD for 40 wk and stimulated with CpG/anti-CD40. Supernatants 
were collected after 20 h of culture and assayed for IL-12p40, IL-6, and 
TNF-α by ELISA. Data are shown as the mean of values from fi  ve mice 
for each group ± the SD. *, P < 0.05; **, P < 0.01, compared with 
indicated controls.JEM VOL. 204, February 19, 2007  445
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TCR-Tg mice (20) into HFCD-fed CD45.2+ apoE−/− or 
CD45.2+ C57BL/6 mice, and then immunized recipients 
with GP61-80 peptide together with CpG. After 4 d, at least 
8–9 cell divisions were detected in both groups of mice. 
However, the extent of proliferation was reduced in HFCD-
fed apoE−/− mice, as compared with chow diet–fed C57BL/6, 
chow diet–fed apoE−/−, and HFCD-fed C57BL/6 controls 
(Fig. 2 B and not depicted), suggesting that CD4 T-cell 
proliferation was aff  ected by severe dyslipidemia. 6 d after 
immuni  zation, we restimulated splenocytes with PMA/iono-
mycin and assessed IL-4 and IFN-γ production by intracellu-
lar cytokine staining. The frequency of IFN-γ–producing 
CD45.1+CD4+ T cells was similar in all four groups of mice, 
whereas the frequency of IL-4–producing CD45.1+CD4+ 
T cells was signifi   cantly increased in HFCD-fed apoE−/− 
mice compared with apoE−/− chow diet, C57BL/6 chow 
diet, and HFCD controls (Fig. 2 C). These data suggest that 
dyslipidemia alters the Th1/Th2 balance in vitro and in vivo 
through a DC-mediated mechanism.
Dyslipidemia impairs TLR-mediated activation of DCs
We next sought to delineate the eff  ect dyslipidemia might 
have on DC function. apoE−/− and C57BL/6 mice were 
maintained for 12 wk on a standard chow diet or HFCD. 
The total number of splenic CD11c+ DCs and the expression 
of costimulatory molecules CD40, CD80, and CD86 under 
steady-state conditions were similar in all four groups of mice 
(unpublished data). However, up-regulation of CD40, 
CD80, and CD86 (Fig. 3 A and not depicted), and the 
  frequency of IL-12p40–producing DCs, were reduced upon 
CpG stimulation of DCs isolated from mice with genetic 
dyslipidemia (apoE−/−) or diet-induced dyslipidemia (Fig. 
3 B). Moreover, DCs from apoE−/− mice mounted reduced 
IL-12p40 and TNF-α responses to stimulation with zymo-
san, poly(I:C), LPS, and imiquimod (R837), which bind to 
TLR2, -3, -4, and -7, respectively, as well as to a combina-
tion of anti-CD40 mAb and CpG (Fig. 3 C).
To further understand the eff  ects of diet, we assessed DC 
function in C57BL/6 mice fed with a HFD. After a long-
term (35–40 wk) HFD, the production of the proinfl  amma-
tory cytokines IL-12p40, IL-6, and TNF-α in response to 
CpG/anti-CD40 stimulation was signifi  cantly impaired (Fig. 
3 D), whereas DCs were not aff  ected after short-term (6–10 wk) 
HFD (not depicted). Together, these results demonstrate that 
both genetic and diet-induced dyslipidemia are associated 
with impaired maturation and activation of DCs by various 
TLR ligands.
Impaired DC maturation and cytokine production 
is restricted to the CD8𝗂− myeloid subset
Splenic CD11c+ DCs can be classifi  ed into CD8α− ( 80% 
of total) and CD8α+ ( 20% of total) subsets that originate 
from myeloid and lymphoid precursors, respectively (21). In-
terestingly, impaired IL-12p40 production by apoE−/− DCs 
was only found in the CD8α−, but not in the CD8α+, DC 
subset (Fig. 4, A and B). DCs require both microbial stimuli 
and CD40 ligation for optimal production of IL-12p70 (22). 
Therefore, we stimulated purifi  ed CD8α− and CD8α+ DCs 
Figure 4.  Impaired production of IL-12, -6, and TNF-𝗂 in dyslip-
idemic mice is restricted to the CD8𝗂− myeloid DC subset. Splenic 
DCs were isolated from HFCD-fed C57BL/6 (B6) or apoE−/− mice and 
stimulated with CpG for 6 h. (A) Representative dot plots from cells stimu-
lated with 100 nM CpG are shown. (B) The proportion of IL-12p40–
  producing cells in CD8α− and CD8α+ DC subsets after stimulation with 
the indicated doses of CpG. (C) Splenic CD8α− DCs and (D) CD8α+ DCs 
were sorted by fl  ow cytometry from C57BL/6 and apoE−/− mice were fed 
either a chow or HFCD for 10 wk and stimulated with CpG and anti-
CD40. Supernatants were collected after 20 h of culture and assayed for 
IL-12p40, -12p35, -6, and TNF-α by ELISA. Error bars represent the mean ± 
the SD.446  DYSLIPIDEMIA NEGATIVELY REGULATES DC ACTIVATION AND TH1 RESPONSES | Shamshiev et al.
with both CpG and agonistic anti-CD40 mAb and measured 
cytokine production in the supernatant. HFCD strikingly in-
hibited the capacity of DCs to produce IL-12p40, -12p70, -6, 
and TNF-α from both C57BL/6 and apoE−/− mice with 
the most severe defect in the latter (Fig. 4 C). In contrast, 
CD8α+ DCs secreted comparable amounts of IL-12p70 and 
-12p40 (Fig. 4 D). To assess whether dyslipidemia aff  ected 
the DC response to TLR stimulation in vivo, we injected 
HFCD-fed apoE−/− or C57BL/6 mice with CpG or LPS, 
and 5 h later we isolated splenic DCs and analyzed expression 
of costimulatory molecules and IL-12p40 production. Con-
sistent with the in vitro results, we observed a reduced ex-
pression of the costimulatory molecules CD80, CD86, and 
CD40 (Fig. 5 A), and a reduced number of IL-12p40–pro-
ducing CD8α− DCs isolated from HFCD-fed apoE−/− mice 
(4.6 ± 1.1%) compared with HFCD-fed C57BL/6 controls 
(15.3 ± 2.4%; Fig. 5 B). Collectively, these results demon-
strate that dyslipidemia inhibits TLR-mediated maturation 
and proinfl  ammatory cytokine production in CD8α− DCs, 
but not in CD8α+ DCs.
Dyslipidemia is responsible for the impaired 
activation of DCs
We next used two strategies to assess whether the impairment 
of DC maturation and cytokine production was caused by 
dyslipidemia or simply associated with the absence of apoE. 
First, we generated BM-derived DCs (BMDCs), which are 
of myeloid origin (23), from chow diet– or HFCD-fed 
C57BL/6 or apoE−/− mice and stimulated them with TLR 
ligands. All BMDCs responded comparably to LPS, CpG, 
and poly(I:C), as determined by surface expression of CD40, 
CD80, CD86, MHC class II, and intracellular staining for 
IL-12p40, IL-6, and TNF-α (Fig. 6 A and not depicted). 
Second, we isolated splenic DCs from apoE−/− mice at 5 wk 
of age, i.e., before they had developed severe dyslipidemia. 
The response of splenic CD8α− DCs isolated from apoE−/− 
mice at 5 wk of age was similar to that of C57BL/6 controls, 
as shown by intracellular staining for IL-12p40 and surface 
staining for CD40 and CD80 (Fig. 6 B and not depicted). 
These results demonstrated that the apoE−/− CD8α− DCs 
were not intrinsically defective because of lack of apoE, and 
that the impaired response to TLR ligands was likely medi-
ated by dyslipidemia.
Circulating oxidized lipids and oxLDL-induced gene 
expression in CD8𝗂− DCs are increased in apoE−/− mice
Our in vitro data showed that CD8α− DCs from apoE−/− 
mice exhibited impaired responses upon TLR stimulation, 
and that this phenomenon correlated with dyslipidemia. Dys-
lipidemia in apoE−/− mice is characterized by increased levels 
of LDL/VLDL, total cholesterol, triglycerides, and altered 
lipid composition of LDL and high-density lipoprotein (12, 
13, 24). In addition, the LDL and VLDL from apoE−/− mice 
are more prone to oxidative modifi  cation (25–29). We mea-
sured levels of circulating oxidized lipids in 5- or 30-wk-old 
mice fed a chow diet. At 5 wk of age, C57BL/6 and apoE−/− 
mice exhibited comparable levels of plasma thiobarbituric 
acid–reactive substrates (TBARS). However, after 30 wk, 
apoE−/− mice presented a statistically signifi  cant increase in 
TBARS (Fig. 7 A). These data are in agreement with previ-
ous fi  ndings, which show the presence of oxidized lipids in 
plasma lipoproteins (30, 31) and age-dependent increment of 
LDL oxidation in apoE−/− mice (26, 32). oxLDL has been 
Figure 5.  Impaired DC maturation and IL-12 production in dyslip-
idemic mice after LPS and CpG challenge in vivo. C57BL/6 (B6) and 
apoE−/− mice were fed HFCD for 12 wk, followed by i.v. injection of PBS, 
10 nmol CpG, or 30 μg LPS. 5 h after administration, splenic DCs were 
purifi  ed and incubated ex vivo for an additional 12 h. (A) CD11c+CD8α− 
DCs were analyzed for the expression of CD40, CD80, and CD86 by fl  ow 
cytometry. The expression levels of CD40, CD80, and CD86 in PBS-injected 
B6 mice (shaded area) and apoE−/− mice (not depicted) were comparable. 
(B) HFCD-fed C57BL/6 or apoE−/− mice were injected i.v. with 10 nmol 
CpG. 5 h later, splenic DCs were purifi  ed and incubated in the presence of 
Brefeldin A, followed by staining for CD11c, CD8α, and IL-12p40. Numbers 
indicate the percentage of cells in each quadrant and represent the mean 
of values from three mice per group. Similar results were obtained with 
cells isolated from mice injected with LPS.JEM VOL. 204, February 19, 2007  447
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shown to bind the scavenger receptor CD36 (33), leading to 
increased CD36 expression (34, 35) and levels of adipocyte 
fatty acid–binding protein (aP2) (36) and ATP-binding 
  cassette A1 (ABCA1) (37). Consistently, we found increased 
CD36 cell surface expression (Fig. 7 B), as well as ABCA1 
and aP2 RNA expression (Fig. 7 C) by CD8α− DCs from 
apoE−/− compared with 30-wk-old C57BL/6 mice. In con-
trast, CD8α+ DCs of C57BL/6 and apoE−/− expressed com-
parable levels of CD36, ABCA1, and aP2 (Fig. 7, B and C). 
Collectively, these results support the conclusion that oxLDL 
aff  ects CD8α− DCs in vivo.
oxLDL inhibits NF-𝗋B nuclear translocation in CD8𝗂− DCs 
and biases their capacity to polarize Th cells
To test whether oxLDL was capable of regulating DC func-
tion directly, we pulsed splenic DCs isolated from chow 
diet–fed C57BL/6 mice with human oxLDL or native LDL 
(nLDL) before stimulation with CpG or imiquimod (R837). 
Intracellular cytokine staining revealed that oxLDL treat-
ment inhibited TLR-induced IL-12p40 production in the 
CD8α− DC subset without aff  ecting the CD8α+ DC sub-
set (Fig. 8 A). Consistent with in vitro fi  ndings, injection of 
oxLDL into C57BL/6 mice inhibited IL-12 production by 
CD8α−, but not CD8α+ DCs upon ex vivo CpG stimula-
tion (Fig. 8 B).
In resting cells, NF-κB proteins are primarily localized in 
the cytoplasm in association with inhibitory proteins. Upon 
TLR ligation, NF-κB is released from the inhibitory proteins 
and subsequently translocates into the nucleus to activate 
proinfl  ammatory gene expression. Consistent with this, we 
found that upon CpG stimulation of CD8α− BMDCs, NF-κB 
p65 accumulated in the nucleus, whereas unstimulated cells 
showed mainly cytoplasmic distribution of NF-κB p65 (Fig. 
8 C). In contrast to nLDL, preincubation of DCs with oxLDL 
prevented CpG-induced translocation of NF-κB p65 into 
the nucleus (Fig. 8 C), and comparable results were found 
upon LPS stimulation (not depicted).
We next sought to investigate the eff  ect of oxLDL on 
Th1/Th2 development in vitro. Thus, DCs were pulsed with 
oxLDL or nLDL before 4-d co-culture with naive TCR-Tg 
CD4+ T cells and a high concentration of specifi  c antigen 
(GP61-80 peptide), which is a condition favoring Th1 devel-
opment (38, 39). The Th1-inducing capacity of DCs was 
considerably impaired upon oxLDL treatment, whereas Th2 
development was enhanced (Fig. 8 D).
D  I  S  C  U  S  S  I  O  N 
Diseases associated with dyslipidemia are responsible for 
widespread morbidity and mortality in industrialized coun-
tries. The dyslipidemia itself has both direct eff  ects upon dis-
ease induction and indirect eff   ects through modulating 
immune responses. In this study, we have addressed the 
mechanism by which dyslipidemia eff  ects immune responses 
in vivo and in vitro. Our data show that CD8α− DCs are 
conditioned by dyslipidemia to be hyporesponsive, fail to 
  induce robust Th1 responses, and preferentially induce Th2 
cell development. Notably, this dyslipidemia-mediated DC 
hyporesponsiveness had striking implications for protective 
immunity in vivo.
To facilitate the development of dyslipidemia, we used 
apoE−/− and C57BL/6 mice fed a HFCD. A series of control 
experiments confi  rmed that the immune bias in these mice 
was caused by dyslipidemia, as opposed to other pathways as-
sociated with the absence of the apoE gene. First, splenic DCs 
isolated from apoE−/− mice at 5 wk of age, i.e., before they 
develop obvious dyslipidemia and lipid peroxidation, showed 
normal unimpaired responses to TLR stimulation. The im-
paired IL-12 production in splenic CD8α− DCs of apoE−/− 
mice was most prominent at 20–30 wk of age, concomitant 
with the development of severe dyslipidemia and accumula-
tion of lipid peroxidation products. This is consistent with 
previous studies showing an age- and diet-dependent increase 
of lipoprotein lipid peroxidation in apoE−/− mice (25, 26, 
31, 32). Second, HFCD, which accelerates severe dyslipidemia, 
further impaired DC function in both apoE−/− and C57BL/6 
Figure 6.  BMDCs generated from HFCD-fed apoE−/− mice and 
splenic DCs from 5-wk-old apoE−/− mice exhibit normal responses 
upon TLR stimulation. (A) C57BL/6 (B6) and apoE−/− mice were fed 
HFCD for 12 wk, and BM cells were pooled from two mice for each group, 
and BMDCs were generated in GM-CSF–containing media, as described in 
the Materials and methods. At day 9 of culture, DCs were stimulated with 
the indicated doses of CpG or LPS for 6 h, followed by surface and intra-
cellular staining. The percentages of CD11c+ and IL-12p40+ cells for each 
BMDC culture are shown. Similar results were obtained with poly(I:C)-
stimulated cells and intracellular staining for IL-6 and TNF-α. (B) Splenic 
DCs were purifi  ed from C57BL/6 (B6) and apoE−/− mice at 5 wk of age 
and stimulated with CpG for 6 h, followed by surface and intracellular 
staining. IL-12p40 production was analyzed in CD8α+ or CD8α− CD11c+ 
DC subsets. The percentages of IL-12p40+ cells for each individual mouse 
are shown (n = 3). 448  DYSLIPIDEMIA NEGATIVELY REGULATES DC ACTIVATION AND TH1 RESPONSES | Shamshiev et al.
mice. Third, BMDCs generated from HFCD-fed apoE−/− 
mice with severe dyslipidemia, in which splenic CD8α− DCs 
were strongly aff   ected, exhibited unimpaired responses to 
TLR stimulation. This data also shows that the lack of apoE 
in the DC, by itself, does not infl  uence DC responses to TLR 
stimulation. In fact, both HFCD and long-term HFD feeding 
of C57BL/6 mice reduced TLR-mediated IL-12, -6, and 
TNF-α production in CD8α− DCs, ruling out a possible 
DC-intrinsic role for apoE. Thus, we propose that CD8α− 
DCs are conditioned by the dyslipidemic microenvironment 
itself, rendering them refractory to stimulation through vari-
ous TLRs, including TLR2, -3, -4, -7, and -9, which use 
MyD88- and/or TRIF-dependent signaling pathways to cul-
minate in NF-κB activation (40). We found that oxLDL pre-
vented nuclear translocation of NF-κB p65 in CD8α− DCs. 
Similarly, oxidized phospholipids that are present in oxLDL 
have been reported to prevent TLR-induced NF-κB activa-
tion in human DC in vitro (41).
Under general conditions, IL-12 plays a central role in the 
diff  erentiation of naive CD4+ T cells into IFN-γ– produc-
ing Th1 cells (4), which is further supported by concurrent 
TLR simulation (42). Our results indicate that dyslipidemia 
strongly reduces IL-12 production and CD40 up-regulation 
by splenic CD8α− DCs, in addition to impairing the quality 
of the TLR signal. Considering that CD40 on DCs is known 
to positively regulate IL-12 production through its interac-
tion with CD40L on activated T cells (22, 38) this path-
way may further compound the immunomodulatory eff  ect 
of dyslipidemia. In addition to reduced expression of IL-12 
and CD40, we found impaired up-regulation of CD80 and 
CD86, which are critical for optimal activation of CD4+ 
T cells (43, 44). The net result of this impaired expression of 
costimulatory molecules and reduced production of IL-12 
was a bias toward Th2 cell polarization.
A surprising fi  nding was that dyslipidemia infl  uenced the 
expression of costimulatory molecules and production of 
  infl  ammatory cytokines exclusively on splenic CD8α− DCs 
without aff  ecting the CD8α+ DC subset. These two DC 
subsets share a common capacity to present antigens to T cells 
and induce Th cell diff  erentiation. It has been suggested that 
CD8α+ DCs induce Th1 cell development, whereas CD8α− 
DCs induce Th2 cell development (45). However, more re-
cent studies showed that the fate of Th cells is greatly infl  u-
enced by the nature and the concentration of the antigen 
Figure 7.  Increased systemic lipid preoxidation and up-regulation 
of CD36 and oxLDL-induced genes in apoE−/− CD8𝗂− DCs. (A) 5- or 
30-wk-old, chow diet–fed C57BL/6 mice and apoE−/− mice were fasted 
for 12 h. TBARS were determined in freshly collected plasma samples 
containing 5 mM EDTA, as described in Materials and methods. (B) CD36 
expression was analyzed in splenic DCs isolated from chow diet–fed 
C57BL/6 (regular line) and apoE−/− (bold line) mice at 30 wk of age. 
  Histograms are representative of data obtained from four mice in each group. 
Mean fl  uorescence intensity values are shown. Shaded and dashed lines 
show staining of C57BL/6 and apoE−/− DCs with an isotype-matched 
control antibody, respectively. (C) CD8α− and CD8α+ DCs were sorted 
from the spleens of chow diet–fed C57BL/6 and apoE−/− mice at 30 wk 
of age. ABCA1 and aP2 mRNA levels were quantified by quantitative 
real time PCR. Horizontal bars indicate mean values for each group 
(n = 8–22). *, P <0.01, compared with corresponding controls. Error bars 
represent the mean ± the SD.JEM VOL. 204, February 19, 2007  449
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(38, 46) and by the activation of DC by microbial stimuli 
(3, 42, 46). Indeed, both CD8α+ and CD8α− DCs are capable 
of inducing either Th1 or Th2 cells, depending on DC stimu-
lating conditions and antigen dose (46, 47).
Our results support previous studies demonstrating that 
severe hypercholesterolemia reduces IgG2a class switch-
ing and enhances KLH-specifi  c IL-4 production (48, 49); 
Th2-biased autoimmune response to the autoantigen malon-
dialdehyde-LDL (50); and provide a mechanism by which 
dyslipidemia infl  uences the immune response. Furthermore, 
using a model of obesity-associated dyslipidemia, our data 
demonstrates that the eff  ect was not caused by hypercholes-
terolemia, by itself, but was instead caused by LDL oxidation, 
and perhaps other disturbances in lipoprotein homeostasis. 
These data are in agreement with previous studies, which show 
the antiinfl  ammatory  eff   ects of oxLDL in LPS-stimulated 
macrophages (51–53) and THP-1 cells (54). Still, it re-
mains possible that in addition to oxLDL, reactive oxygen 
species, including H2O2, which is elevated in dyslipidemic 
conditions (55), may contribute to the impaired DC function 
in vivo. Additional studies will be required to further defi  ne 
the molecular pathways regulating DC function and Th cell 
diff   erentiation in dyslipidemia and to identify the down-
stream lipid metabolites responsible for the inhibitory eff  ect 
of oxLDL.
Finally, our results have demonstrated that dyslipidemia 
increases host susceptibility to the intracellular protozoan 
L. major, which is normally controlled by Th1 immune re-
sponses. TLR signaling via MyD88-dependent pathways and 
IL-12 production have been shown to be critical to combat 
L. major infection (5, 6, 56). We have recently described that 
LN-resident, conduit-associated CD8α− DCs initiate T-cell 
responses to L. major (57). Thus, reduced activation and IL-12 
production by these resident CD8α− DCs, concomitant with 
increased frequency of Th2 cytokine-producing cells, is 
probably responsible for increased susceptibility to L. major in 
dyslipidemic mice. Angeli et al. previously suggested that im-
paired contact hypersensitivity and delayed-type hypersensi-
tivity are caused by impaired migration of skin DCs in 
apoE−/− and LDLr−/− mice (18). Consistently, we found that 
migration of lung and skin DCs to the DLN was reduced in 
dyslipidemic apoE−/− mice immunized with FITC-coupled 
ovalbumin (our unpublished data). Thus, although migration 
of skin DCs is not critical for activation of T cell responses to 
L. major (57), it may contribute to impaired immune re-
sponses in other models (18). In fact, impaired DC migration 
in apoE−/− mice may be a consequence of reduced activation 
and IL-12p40 (homodimer) production, which has recently 
been shown to have a potent in vivo chemoattractant activity 
on DCs (58, 59).
Figure 8.  oxLDL inhibits CpG-induced IL-12p40 production and 
NF-𝗋B nuclear translocation in CD8𝗂− DCs, and promotes Th2 cell 
differentiation. (A) C57BL/6 splenic DCs were incubated with 40 μg/ml 
nLDL or 40 μg/ml oxLDL for 1 h at 37°C. After washing, DCs were acti-
vated with 100 nM CpG or 5 μg/ml R837 for 6 h, followed by surface 
staining for CD11c and CD8α, and intracellular staining for IL-12p40. 
Gated on CD11c+ cells. The numbers indicate the percentage of cells in 
each quadrant. (B) C57BL/6 mice (n = 3) were injected i.v. with 2 mg/dose 
of either nLDL or oxLDL. After 3 h, splenic DCs were ex vivo stimulated 
with CpG and stained as described for A. (C) BMDCs were cultured on 
coverslips and incubated with 60 μg/ml nLDL or 60 μg/ml oxLDL for 1 h, 
and then stimulated with 300 nM CpG for 30 min at 37°C. Cells were 
permeabilized and immunostained with anti–NF-κB p65 and Alexa Fluor 
goat anti–rabbit IgG (green, top); nuclei were stained with DAPI (blue, 
bottom). (D) C57BL/6 splenic DCs were exposed to10 μg/ml nLDL or 
10 μg/ml oxLDL for 1 h and co-cultured with naive GP61-80-specifi  c CD4+ 
T cells in the presence of 100 nM GP61-80 peptide. At day 4, T cells were 
restimulated with PMA/ionomycin and stained for intracellular IL-4 and 
IFN-γ. Gated on CD4+ T cells. The numbers indicate the percentage of 
cells in each quadrant.450  DYSLIPIDEMIA NEGATIVELY REGULATES DC ACTIVATION AND TH1 RESPONSES | Shamshiev et al.
In conclusion, we have shown that dyslipidemia inhibits 
activation and infl  ammatory cytokine production by CD8α− 
DCs and deviates the ensuing T cell immunity. Our fi  ndings 
have implications for the understanding of the immune 
mechanisms underlying many pathological conditions in 
  humans, including metabolic syndrome, atherosclerosis, 
and obesity, which are strongly associated with dyslipidemia.
MATERIALS AND METHODS
Animals. C57BL/6 mice (Charles River Laboratories), apoE−/− mice back-
crossed to C57BL/6 >10 times (The Jackson Laboratory), and Smarta-2 
(a lymphocytic choriomeningitis virus glycoprotein GP61-80) TCR-Tg (I-Ab) 
mice (20) were maintained in specifi   c pathogen-free conditions. Age-
matched (9–12-wk-old) female mice were maintained under either a stan-
dard chow diet (3436; Provimi Kliba SA), a HFCD (D12108; Research 
Diets, Inc.), containing 20% fat and 1.25% cholesterol, or a HFD (2127; 
Provimi Kliba SA) containing 35% fat and 0.03% cholesterol for the times 
indicated in the fi  gure legend. All animal experiments were approved 
and performed under the guidelines set by the State Veterinary Offi   ce of 
Zürich, Switzerland.
Reagents. Human nLDL (RP-031) and oxLDL (RP-047) were obtained 
from Intracel Resources. LPS from Escherichia coli 0111:B4 and zymosan 
were purchased from Sigma-Aldrich. Phosphorothioate CpG (T  C  C  A  T  G  A-
C  G  T  T  C  C  T  G  A  T  G  C  T  ) was synthesized by Microsynth AG. Poly(I:C) and 
imiquimod (R837) were obtained from InvivoGen.
Isolation of splenic DCs, naive CD4+ T cells, and in vitro diff  eren-
tiation of CD4+ T cells. Splenic CD11c+ DCs were positively sorted 
from single-cell suspensions of the spleens of C57BL/6 and apoE−/− mice, 
and naive CD4+ T cells were positively sorted from Smarta-2 Tg mice ex-
pressing a TCR specifi  c for GP61-80 peptide (20) using magnetic beads (Milt-
enyi Biotec), and in vitro diff  erentiation of naive CD4+ T cells was performed 
as previously described (42). For some experiments, splenic CD11c+CD8α− 
and CD11c+CD8α+ DCs were positively selected from the pooled spleens 
and sorted using a FACSVantage (97–98% purity; BD Biosciences).
Analysis of cell surface marker expression and detection of intra-
cellular cytokines. FITC-, PE-, or allophycocyanin (APC)-conjugated anti-
bodies specifi  c for CD4, Vα2 TCR, CD62L, CD11c, CD40, I-Ab, CD80, 
CD86, and CD36 were used for surface staining of CD4+ T cells and DCs. 
For analysis of DC cytokines, purifi  ed DCs were stimulated with the indi-
cated TLR ligands for 2 h and incubated with 10 μg/ml Brefeldin A for an 
additional 4 h. In some experiments, the combination of CpG and CD40 
antibodies was used for DC activation. DCs were surface stained with anti-
CD11c and anti-CD8α, fi  xed in 2% paraformaldehyde for 20 min on ice, 
permeabilized in 0.5% saponin, and stained intracellularly with anti–
IL-12p40-APC, anti–IL-6-PE, or anti–TNF-α–FITC. For analysis of T cell 
cytokines, CD4+ T cells were stimulated with PMA/ionomycin for 2 h, 
  before the addition of 10 μg/ml Brefeldin A for an additional 2 h. Cells were 
surface stained with anti-CD4 Abs, fi  xed, and permeabilized like the DCs, 
and stained with anti–IFN-γ–APC, anti–IL-4–PE, or anti–IL-5–FITC. 
Flow cytometry was performed with a FACSCalibur (BD Biosciences) and 
results were analyzed with FlowJo v6.4.7. (Tree Star, Inc.). All antibodies 
were obtained from BD Biosciences.
Adoptive transfer and in vivo activation of naive CD4 T cells. Naive 
CD4+ T cells were labeled with 2.5 μM CFSE (Invitrogen) for 7 min at 
room temperature and i.v. injected (5 × 106 cells/mouse) into mice 1 d be-
fore immunization. At day 0, mice were immunized i.p. with 40 μg GP61-80 
peptide and 5 nmol CpG DNA mixed in PBS. At day 3, splenocytes were 
stained for CD45.1, and cell division was analyzed by fl  ow cytometry. To 
detect cytokines produced by adoptively transferred T cells, mice were killed 
at day 6, and splenocytes were restimulated with PMA/ionomycin for 2 h, 
and incubated with 10 μg/ml Brefeldin A for an additional 6 h, followed by 
surface staining for CD45.1 and intracellular staining for IFN-γ and IL-4.
L. major infection and in vitro restimulation of LN cells. L. major 
promastigotes WHOM/IR/-/173 (provided by N. Glaichenhaus, Univer-
sité de Nice-Sophia Antipolis, Valbonne, France), and MHOM/IL/81/FE/
BNI (provided by C. Bogdan, University of Freiburg, Freiburg, Germany) 
were grown as previously described (57). Anesthetized mice were infected in 
their hind footpad with 2 × 106 metacyclic promastigotes. The size of the 
footpad lesion was monitored using calipers and presented as the mean value ± 
the SD from groups of mice (n ≥ 8). The parasite load was determined using 
a quantitative limiting-dilution assay. In brief, the footpads and DLN were 
homogenized and serially diluted in Schneider’s medium (Cambrex Bio Science) 
supplemented with 20% FCS, and then cultured for 7–10 d at 26°C. Parasite 
burden was expressed as the greatest dilution at which promastigote growth 
was observed. L. major lysate was prepared by freezing and thawing in PBS, 
and then being centrifuged at 10,000 g for 10 min at 4°C. The protein con-
centration in the supernatant containing soluble antigens was determined by 
the Bradford method using Protein Assay Dye Reagent (Bio-Rad Laboratories). 
Cell suspensions were prepared from DLN at the indicated times after infec-
tion and stimulated with either PMA/ionomycin or L. major lysate for 6 h, 
followed by fi  xation and surface staining for CD4 and intracellular staining 
for IFN-γ, IL-4, and -5.
Real-time quantitative PCR. Total RNA was isolated using TRI Re-
agent (Molecular Research Center, Inc.) and treated with DNase   (Invitrogen) 
to avoid genomic DNA contamination, followed by reverse transcription 
using SuperScript III RT (Invitrogen). Quantitative real-time RT-PCR was 
performed using Brilliant SYBR Green (Stratagene) on an iCycler (Bio-Rad 
Laboratories). Expression was normalized to β-actin control. Primer 
  sequences are available upon request.
Immunofl  uorescence analysis. BMDCs were generated as previously de-
scribed (60) and cultured on coverslips for 3 d. After treatments, cells were fi  xed 
in paraformaldehyde (2%) and permeabilized in 0.4% Triton X-100 in PBS. 
The coverslips were incubated with anti–NF-κB p65 antibodies (sc-7151) in 
0.1% Triton X-100 containing 2% goat serum in PBS. Secondary antibodies 
were Alexa Fluor goat anti–rabbit IgG (Invitrogen). Nuclei were stained with 
DAPI. The coverslips were mounted on glass slides, and stained cells were ex-
amined on a fl  uorescence microscope (Axioplan 2; Carl Zeiss MicroImaging, 
Inc.). All cell images were obtained with equal exposure time.
Cytokine detection by ELISA. Culture supernatants were harvested at 
the indicated times, and TNF-α, IL-6, -12p70, and -12p40 were measured 
by sandwich ELISA. All antibodies were obtained from eBioscience.
Determination of lipid peroxidation products. Mice were fasted for 12 h 
before bleeding. The levels of TBARS were determined in freshly collected 
plasmas by OXItek assay kit (Alexis Corp.) fl  uorometrically according to 
manufacturer’s instructions.
Statistics. Data are expressed as the mean ± the SD. Statistical comparisons 
were made using the two-tailed Student’s t test.
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